Lung-RADS Tells You the Category.
LungAI Tells You the Probability.
The first reimbursed CADx that scores every nodule 0 to 100, with automatic prior-scan comparison, embedded directly inside the CADe viewer your radiologist already uses.
vs Lung-RADS 0.88
Vision Transformer
under CPT 0721T
Up to 4 in 10 Lung Cancer Diagnoses are Wrong
Lung-RADS v2022 depends entirely on human judgement, a manual rule-based scoring system with no AI and no patient personalization.
AI That Sees What Lung-RADS Misses
LungAI integrates directly into your existing CADe workflow to deliver a continuous 0–100 malignancy risk score per nodule, backed by a 100-million-parameter model trained on 100,000 CT scans and reimbursable under CPT 0721T.
One Platform. Full Funnel.
From patient identification to reimbursable diagnosis, Oatmeal Health covers the entire lung cancer screening journey.
Our AI analyzes EHR data: notes, labs, imaging, billing codes, to predict patients with 20+ pack-year smoking history, even when undocumented. 9x faster than manual chart review with 0.97 AUROC.
AI navigators help FQHC nurse practitioners conduct shared-decision making visits via telehealth. We help educate patients and drive a 91% scan agreement rate, feeding the diagnostic pipeline.
Our 100M-parameter Vision Transformer delivers automated malignancy risk assessments through native integration with PACS/CADe vendors. Nodule-level inference with longitudinal tracking.
Value for Every Stakeholder
Earlier detection increases survival from 9% to 77-92%. Fewer unnecessary biopsies mean less anxiety and fewer complications.
New CPT code 0721T generates $650/scan. Monetize existing CTs with no added work, plus improve radiologist accuracy.
Billable CADx diagnostic layer with shared revenue: from $5/scan to $110/scan. Competitive differentiation and expanded market footprint.
Avoid $600K+ in late-stage treatment costs. Achieve 4-6x ROI from prevention. Improved outcomes for HEDIS quality metrics.











